semaglutide fda news The approved a pill version of the GLP-1 receptor agonist (Wegovy), making it the first oral GLP-1 agent indicated for weight loss, Novo Nordisk announced on Monday. The once-daily 25 Ozempic and Wegovy removed from

CDC also states vaccination reduces hospitalizations and deaths

More recently, the SELECT trial confirmed cardiovascular benefits of Wegovy in patients with overweight/obesity and established cardiovascular disease without diabetes, leading to its 2024 FDA indication for cardiovascular risk reduction in this population

Satish A, Punith Kumar R, Rakshith D, Satish S, Ahmed F

lupus, how fibromyalgia and lupus are each diagnosed, and how treatments for fibromyalgia and lupus differ

Start A Clinician-Guided GLP-1 Plan With Healthon Starting semaglutide under clinician supervision ensures your treatment is safe, personalized, and effective